MaxCyte IPO Presentation Deck

High Cell Viability and Transfection Efficiency across a Variety of Cell Types Ten different cell types were transfected with PGFP DNA using pre- loaded protocols on the MaxCyte STX platform. The results showed that cell viability and transfection efficiency exceeded 90 % across all cell types using MaxCyte's STx platform. CHO 90% Viable 90% GFP Hola 92% Viable 90% GFP Huh-7 90% Viable 80% GFP K562 90% Viable 90% GFP- Vero 90% Viable 90% GFP Renca 97% Viable 80% GFP July 2021 NIH 3T3 90% Viable 90% GFP Primary Fibroblasts 95% Viable 96% GFP hMSCs 80% Viable 80% GFP HEK 293 95% Viable 96% GFP Figure 1: The MaxCyte STX comes preloaded with optimized electroporation protocols for a variety of cell types. Ten different cell types were transfected with 2 µg/1E6 cells of PGFP DNA using the appropriate MaxCyte STX protocol. 24 hours post transfection cells were examined for cell viability (% cells excluding propidium iodide, Pl) and transfection efficiency (% cells GFP). High viability and efficiency across many cell types A study published in Nature Immunology from a leading US academic institution examined the CRISPR-Cas9-mediated gene knockdown of murine primary T cells using CRISPR ribonucleoproteins (RNPs). The study demonstrated RNP transfection efficiencies were consistently greater than 90% using MaxCyte's ATX platform. Quantification of cell viability and transfection efficiency of RNP and RNP CONFIDENTIAL b SSC FSC 08/peagwNT CD4-8V510 4 ATTO-550 RNP RNP Cell Viability Live CD4 (%) Electroporation Efficiency RNP* (%) RNP transfection efficiencies were consistently greater than 90% and >85% cell viability with MaxCyte ATX Customer generated data showed high viability and efficiency in T-cells 31

View entire presentation